JAMA lambastes Vioxx articles

The Journal of the American Medical Association called into question published clinical data and authorship surrounding Merck's Vioxx (rofecoxib) in a scathing editorial. 

The hubbub stems from two articles printed in the April 16 issue, which offer a microscopic look at documents obtained during Vioxx lawsuits and litigation.

JAMA asserts that “clinical trial articles and review articles related to rofecoxib frequently were written by unacknowledged authors who were employees of for-profit information industries…” Merck refuted the charges in a statement claiming that the JAMA reports related to Vioxx “are false, misleading or lack context.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.